Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R²) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma – Journal of Clinical Oncology

Commentaries:

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma – The ASCO Post

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma – OncLive

Commentary on Twitter

6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc

— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022